J Bone Metab.
2020 Aug;27(3):175-186. 10.11005/jbm.2020.27.3.175.
Use of Bisphosphonates, Calcium and Vitamin D for Bone Demineralization in Patients with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome: A Systematic Review and Meta-Analysis of Clinical Trials
- Affiliations
-
- 1Department of General and Specialized Surgery, Medical School, Federal University of the State of Rio de Janeiro, RJ, Brazil
- 2Department of Orthopedics and Traumatology, Gaffrée and Guinle University Hospital, RJ, Brazil
- 3Dertment of Orthopedics and Traumatology, Central Brazilian Army Hospital, RJ, Brazil
- 4Department of Clinical Pathology, National Institute of Traumatology and Orthopedics, RJ, Brazil
- 5Department of Statistics, Institute of Mathematics, Federal Fluminense University, RJ, Brazil
- KMID: 2506160
- DOI: http://doi.org/10.11005/jbm.2020.27.3.175
Abstract
- Background
The present study performed a systematic review and meta-analysis of clinical trials using bisphosphonates for bone demineralization in human immunodeficiency virus (HIV) patients.
Methods
A comprehensive literature search was performed from January 2004 to January 2020 considering the bone mineral density (BMD) of the lumbar spine (LS) as the main outcome. Out of 214 titles that met criteria, 9 studies fulfilled the selection criteria.
Results
A total of 394 patients were identified, and they were allocated into 2 groups: the intervention group (200 patients), to whom a combination of alendronate or zoledronate with calcium and vitamin D was administered; and control group (194 patients), to whom only calcium and vitamin D was administered. Clinical profile and indicators of bone metabolism of the participants were evaluated regarding effect size, homogeneity, and consistency. No substantial heterogeneity between the groups was found for the baseline variables, and there was high consistency to the main outcome. The meta-analysis shows a significant difference in post-treatment BMD, favoring the intervention over the control treatment. The intervention improved LS density up to 0.227 g/cm², raising the average to the levels of general population. Adverse effects related to intervention were fever immediately after zoledronate administration and gastrointestinal complaints during alendronate usage. Other adverse effects were barely reported and poorly connected to intervention by studies’ authors, despite all of them have been successfully resolved.
Conclusions
This study provides evidence that BMD post-treatment is better in HIV patients who used bisphosphonates combined with calcium and vitamin D.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Vitamin B12 Deficiency Megaloblastic Anemia in a Patient with Acquired Immunodeficiency Syndrome
- The 2015 Clinical Guidelines for the Treatment and Prevention of Opportunistic Infections in HIV-Infected Koreans: Guidelines for Opportunistic Infections
- New Insight into the Action of Vitamin D
- Molluscum Contagiosum as a Skin Manifestation of Immune Reconstitution Inflammatory Syndrome in an AIDS Patient Who Is Receiving HAART
- Paradoxical Cryptococcal Meningitis Immune Reconstitution Inflammatory Syndrome in a Patient with Human Immunodeficiency Virus Infection: Matching Clinical Findings with MRI Findings
